Global Pentavalent Market Size Study & Forecast, by Type (Sodium Stibogluconate, Meglumine Antimoniate), by Formulation Type (Lyophilized, Liquid), by Application (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2023-203

Global Pentavalent Market Size Study & Forecast, by Type (Sodium Stibogluconate, Meglumine Antimoniate), by Formulation Type (Lyophilized, Liquid), by Application (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2023-2030

Global Pentavalent Market is valued at approximately USD 2.43 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 5.1% over the forecast period 2023-2030. Pentavalent is a kind of vaccine that protects against five different diseases: diphtheria, pertussis (whooping cough), tetanus, hepatitis B, and Haemophilus influenzae type b (Hib). It is called a ""pentavalent"" vaccine as it contains five different vaccines in one shot. The Pentavalent Market is expanding because of factors such as increasing government initiatives, increasing number of immunization programs, and rising healthcare expenditure.

Diphtheria results in serious difficulties breathing and eating, as well as the potential for skin ulcers. The three-dose schedule of the pentavalent vaccine protects children from diphtheria diseases; as a result, demand for pentavalent vaccines soared as diphtheria became more common. Thus, the rising prevalence of diphtheria is driving the market growth. For instance, the International Health Regulations (IHR) reporting process recorded an unusually high number of reported cases of diphtheria in 2022, primarily in the months of June and August. According to the World Health Organization, a specialized agency of the United Nations with headquarters in Switzerland. 144 cases of diphtheria have been reported from seven different countries, many of whom were refugees. Among 144 individuals, 44 (31%) were found to have toxigenic diphtheria by laboratory confirmation, 97 (69%) were found to be clinically compatible, and 3 (2%), suspected instances. As a result, the market is expanding because of the increasing occurrence of diphtheria. In addition, increasing strategic initiatives by the key market players and growing R&D spending on pentavalent vaccine development activities is creating lucrative growth in the market. However, the high initial cost of pentavalent development and lack of awareness stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Pentavalent Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players and the region's increasing disease prevalence, and rising investment in research and development activities. Asia Pacific is expected to grow at the highest CAGR during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for vaccine development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Sanofi
GlaxoSmithKline PLC.
Bristol-Myers Squibb Company
Maiden Pharmaceuticals Limited
Shandong Xinhua Pharmaceutical Co.,Ltd.
Panacea Biotec Ltd.
Biological E. Ltd.
Novartis AG
Shantha Biotechnics Ltd.
Serum Institute of India Pvt. Ltd.

Recent Developments in the Market:
In December 2022, The United States Food and Drug Administration, a US federal agency of the Department of Health and Human Services, approved Pfizer's Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY in Adolescents), which is indicated for the prevention of meningococcal disease in people aged 10 to 25.

In January 2022, Ardian, a private equity investment firm with headquarters in France, acquired Biofarma Group. Ardian would be able to facilitate the market's further international expansion and consolidation with this acquisition. The Biofarma Group is an Italian business that competes in the market for pentavalent vaccines.

Global Pentavalent Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Type, Formulation Type, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Sodium Stibogluconate
Meglumine Antimoniate

By Type:
Lyophilized
Liquid

By Application:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Sanofi
GlaxoSmithKline PLC.
Bristol-Myers Squibb Company
Maiden Pharmaceuticals Limited
Shandong Xinhua Pharmaceutical Co.,Ltd.
Panacea Biotec Ltd.
Biological E. Ltd.
Novartis AG
Shantha Biotechnics Ltd.
Serum Institute of India Pvt. Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.